Fitzgerald was at the vanguard of American artists critically engaging with television as a medium, figuring in several ...

For older adults, the flu vaccine could look a little different this year. Last week, the US Food and Drug Administration ...

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was ...

Moderna’s newly approved vaccine could allow manufacturers to respond more rapidly to changing influenza strains.

Good news strikes from an unlikely source. On Aug. 6, the Food and Drug Administration approved Replimune’s immunotherapy for metastatic melanoma, a day after it green-lighted mFlusiva, Moderna’s mRNA ...

The Moderna and Replimune approvals are positive signs that the new leadership may be mounting a much-needed turnaround. Dr. Mikhail recently announced several initiatives to streamline the FDA’s ...

After several disastrous flu seasons, there is some good news: The U.S. Food and Drug Administration approved a new, more ...

The Food and Drug Administration just approved the new type of flu vaccine for adults ages 50 and older. It relies on the ...

The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 years and older, with accelerated approval for those 65 and older.

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc.

The vaccine, called mFLUSIVA, is expected to be a versatile new option for people seeking protection from influenza and an important step forward for the widespread adoption of mRNA technology.